From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment
Ā | Not Triaged (NĀ =ā3120) | Triaged (NĀ =ā3656) | |||
---|---|---|---|---|---|
n (%) | n (%) | Unadjusted Prevalence ORa (95% CI) | Adjusted Prevalence ORb (95% CI) | Triage Ratio | |
Province | |||||
āCarazo | 1062 (54.1) | 900 (45.9) | Ref | Ref | Ref |
āChinandega | 1482 (48.9) | 1546 (51.1) | 1.23 (1.10ā1.38)* | 1.23 (1.09ā1.38)* | 1.11 |
āChontales | 576 (32.3) | 1210 (67.8) | 2.48 (2.17ā2.81)* | 2.78 (2.43ā3.19)* | 1.48 |
Age, years | |||||
ā<ā30 | 28 (50.0) | 28 (50.0) | Ref | Ref | Ref |
ā30ā39 | 1812 (46.3) | 2103 (53.7) | 1.16 (0.68ā1.97) | 1.18 (0.69ā2.02) | 1.07 |
ā40ā49 | 747 (43.3) | 979 (56.7) | 1.31 (0.77ā2.23) | 1.36 (0.79ā2.34) | 1.13 |
ā50ā59 | 512 (49.2) | 528 (50.8) | 1.03 (0.60ā1.77) | 1.07 (0.62ā1.86) | 1.02 |
ā60+ | 19 (54.3) | 16 (45.7) | 0.84 (0.36ā1.96) | 0.89 (0.38ā2.11) | 0.91 |
āUnknown | 2 (50.0) | 2 (50.0) | 1.00 (0.13ā7.60) | 0.63 (0.08ā4.97) | 1.00 |
HPV Screening Modality | |||||
āSelf-collected | 3019 (45.9) | 3559 (54.1) | Ref | Ref | Ref |
āProvider-collected | 27 (24.1) | 85 (75.9) | 2.67 (1.73ā4.13)* | 2.82 (1.82ā4.39)* | 1.40 |
āUnknown | 74 (91.9) | 12 (14.0) | 0.14 (0.07ā0.25)* | 0.07 (0.04ā0.14)* | 0.26 |